Since the takeoff of interest in psychedelics, there’s been an attempt to draw parallels to the pharma space. As such, there’s been anticipation and murmuring about when a deal could take place between a big-name, established pharma player and an up-and-coming psychedelics company. That event may still be far away from where the industry is currently, according to experts. Ramkellawan told INN that there’s no denying pharma is looking at this sector, and is perhaps even closer than expected at this point. However, the time of entry won’t be rushed or based on hype, the expert said. “They're not going to just come in and (acquire) someone who is growing some psilocybin. They're not interested in that,” Ramkellawan said. “But if someone does the data on something that has some sort of formulation that they could patent and then they have good early phase results, I can see pharma coming in.” Ramkellawan, who has a pharmaceutical business background, said she has heard from biopharma companies wanting to be kept in the loop on the psychedelics industry. Doug Drysdale, CEO of Cybin (NEO:CYBN,NYSEAMERICAN:CYBN), told INN that when it comes to 2022 he expects “to see some potential consolidation and M&A transactions.” The executive affirmed that psychedelics are here to stay, and in 2022 there will be critical developments on clinical trials using these substances.